In vitro maturation

Authors

  • Wendy Vitek MD,

    Assistant Professor, Corresponding author
    1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Strong Fertility Center, Rochester, NY, USA
    Search for more papers by this author
  • Jared C Robins MD

    Associate Professor
    1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, The Warren Alpert School of Medicine at Brown University, Women and Infants Hospital of Rhode Island Providence, USA
    Search for more papers by this author

Abstract

Key content

  • In vitro maturation is an alternative to in vitro fertilisation for young women with polycystic ovary syndrome and young ovulatory women.
  • In vitro maturation accomplishes the maturation of immature oocytes in the laboratory, thus minimising or avoiding gonadotrophin stimulation and the associated cost, side-effects and risks.
  • Pregnancy rates are lower with in vitro maturation than with in vitro fertilisation.

Learning objectives

  • To define appropriate candidates for in vitro maturation.
  • To review variations in protocols and laboratory aspects of in vitro maturation and the rationale for these variations.
  • To highlight outcome data from in vitro maturation cycles.

Ethical issues

  • Infertile couples must consider both the risks and benefits of in vitro maturation and make an informed decision regarding their treatment options.
  • Further long-term outcome data regarding the health of children born through in vitro maturation is necessary.

Ancillary